Pre-diagnostic plasma advanced glycation end-products and soluble receptor for advanced glycation end-products and mortality in colorectal cancer patients.

Autor: Li J; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Roshelli Baker J; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA., Aglago EK; Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France., Zhao Z; Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA., Jiao L; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Freisling H; Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France., Hughes DJ; Cancer Biology and Therapeutics Group, School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland., Eriksen AK; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Danish Cancer Society Research Center, Copenhagen, Denmark., Tjønneland A; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Danish Cancer Society Research Center, Copenhagen, Denmark., Severi G; Paris-Saclay University, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France.; Department of Statistics, Computer Science, Applications 'G. Parenti', University of Florence, Florence, Italy., Katzke V; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kaaks R; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Schulze MB; Department of Molecular Epidemiology, German Institute for Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.; Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany., Masala G; Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy., Pala V; Epidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Pasanisi F; Dipartimento Di Medicina Clinica E Chirurgia, Federico II University, Naples, Italy., Tumino R; Hyblean Association for Epidemiological Research, AIRE ONLUS, Ragusa, Italy., Padroni L; Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, and Center for Cancer Prevention (CPO), Turin, Italy., Vermeulen RCH; Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands., Gram IT; Faculty of Health Sciences, Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Braaten T; Faculty of Health Sciences, Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Jakszyn PG; Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain., Sánchez MJ; Escuela Andaluza de Salud Pública (EASP), Granada, Spain.; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain., Gómez-Gómez JH; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain., Moreno-Iribas C; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Instituto de Salud Pública y Laboral de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Amiano P; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain.; BioGipuzkoa (BioDonostia) Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain., Papier K; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Weiderpass E; International Agency for Research on Cancer, World Health Organization, Lyon, France., Huybrechts I; Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France., Heath AK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK., Schalkwijk C; Laboratory of Metabolism and Vascular Medicine, Department of Internal Medicine, Maastricht University Medical Center, The Netherlands., Jenab M; Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France., Fedirko V; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2024 Dec 01; Vol. 155 (11), pp. 1982-1995. Date of Electronic Publication: 2024 Jul 26.
DOI: 10.1002/ijc.35114
Abstrakt: Advanced glycation end-products (AGEs), formed endogenously or obtained exogenously from diet, may contribute to chronic inflammation, intracellular signaling alterations, and pathogenesis of several chronic diseases including colorectal cancer (CRC). However, the role of AGEs in CRC survival is less known. The associations of pre-diagnostic circulating AGEs and their soluble receptor (sRAGE) with CRC-specific and overall mortality were estimated using multivariable-adjusted Cox proportional hazards regression among 1369 CRC cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Concentrations of major plasma AGEs, N ε -[carboxy-methyl]lysine (CML), N ε -[carboxy-ethyl]lysine (CEL) and N δ -[5-hydro-5-methyl-4-imidazolon-2-yl]-ornithine (MG-H1), were measured using ultra-performance liquid chromatography mass-spectrometry. sRAGE was assessed by enzyme-linked immunosorbent assay. Over a mean follow-up period of 96 months, 693 deaths occurred of which 541 were due to CRC. Individual and combined AGEs were not statistically significantly associated with CRC-specific or overall mortality. However, there was a possible interaction by sex for CEL (P interaction  = .05). Participants with higher sRAGE had a higher risk of dying from CRC (HR Q5vs.Q1  = 1.67, 95% CI: 1.21-2.30, P trend  = .02) or any cause (HR Q5vs.Q1  = 1.38, 95% CI: 1.05-1.83, P trend  = .09). These associations tended to be stronger among cases with diabetes (P interaction  = .03) and pre-diabetes (P interaction  <.01) before CRC diagnosis. Pre-diagnostic AGEs were not associated with CRC-specific and overall mortality in individuals with CRC. However, a positive association was observed for sRAGE. Our findings may stimulate further research on the role of AGEs and sRAGE in survival among cancer patients with special emphasis on potential effect modifications by sex and diabetes.
(© 2024 UICC.)
Databáze: MEDLINE
Externí odkaz: